Clinical trials: Hodgkin Lymphoma
Lymphoma, Follicular, Lymphoma, Mantle-Cell
A Phase 1 Study of ADI-001 in B Cell Malignancies
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- GLEAN-1 (NCT04735471)
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Adicet Therapeutics
Acute Lymphoblastic Leukemia, Hodgkin Disease
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD
With increasing cure rates of childhood cancer there is growing recognition of late effects of treatments. However, there is a lack of non-invasive and child-friendly procedures that can indicate possible late damage.
- Conditions
- Acute Lymphoblastic Leukemia, Hodgkin Disease, Allogeneic Stem Cell Transplantation
- Trial name
- MinimALL (NCT06093334)
- Testing
- Low-field magnetic resonance imaging, Cardiopulmonary testing, Pulmonary testing
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Non-Hodgkin's Lymphoma
High Dose CHOP in Lymphoma
The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome.
- Trial name
- NCT00192764
- Testing
- high-dose cyclophosphamide
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Rambam Health Care Campus
Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00703664
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003942
- Testing
- RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Systemix
Lymphoma, Non Hodgkin
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's…
- Trial name
- NCT01987505
- Testing
- Rituximab
- Where
- 39 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Extranodal NK-T-Cell
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma…
- Trial name
- NCT04417166
- Testing
- Pembrolizumab, Involved Field Radiation Therapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous…
- Conditions
- Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma
- Trial name
- S-BR (NCT02623920)
- Testing
- Brentuximab, Bendamustine, Rituximab
- Where
- United States
- Sponsor
- University of Arizona
Hodgkin Lymphoma, Adult
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
- Trial name
- NCT06984146
- Testing
- Nivolumab, Doxorubicin, Vinblastine
- Where
- Russia
- Volunteers
- 54 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Mantle Cell Lymphoma
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
This study is designed to evaluate the efficacy and safety of acalabrutinib plus bendamustine and rituximab followed by acalabrutinib plus cytarabine and rituximab in subjects with treatment naïve mantle cell lymphoma (MCL), as a…
- Trial name
- NCT03623373
- Testing
- Bendamustine, Rituximab, Acalabrutinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Non-Hodgkins Lymphoma
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).
Patients with aggressive Non-Hodgkin-lymphoma treated at first diagnosis with chemotherapy alone or combined chemo-radiotherapy can achieve high response rates.
- Trial name
- NCT00301288
- Testing
- Autologous stem cell transplant
- Where
- United Kingdom
- Volunteers
- 152 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Advanced Solid Tumor, B Cell Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma.
- Trial name
- NCT04418141
- Testing
- CN1
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
Non-Hodgkin's Lymphoma
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
This is an open-label multicenter, study to assess the pharmacokinetic interaction of rifampin with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT01969682
- Testing
- ABT-199, Rifampin
- Where
- United States
- Sponsor
- AbbVie
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa Associated Lymphoid Tissue (MALT) lymphoma presenting…
- Trial name
- NCT01611259
- Testing
- Rituximab and Lenalidomide
- Where
- 5 sites in Austria
- Volunteers
- 50 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Dementia, Mild, Depressive Disorder
Dignity Therapy for Patients With Early Dementia and Their Family
Developed by Harvey M. Chochinov in 2005, Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
- Trial name
- DTD (NCT03692988)
- Testing
- Dignity Therapy
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- University of Zurich
Non-Hodgkin's Lymphoma
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP).
- Trial name
- NCT00336583
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Asan Medical Center
Chronic Kidney Disease, Stage 3 (Moderate)
Short-term Effect of a New Nordic Renal Diet on Phosphorus Homeostasis in CKD Stage 3-4
Hyperphosphatemia is a severe complication to chronic kidney disease (CKD) and is associated with increased risk of vascular calcification, cardiovascular morbidity and mortality.
- Trial name
- NCT03472105
- Testing
- New Nordic Renal Diet
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- University of Copenhagen
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
The purpose of this study is to determine safety, tolerability, dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory lymphoproliferative malignancies (LPM) or…
- Trial name
- NCT02238522
- Testing
- ZEN003365
- Where
- 4 sites in United States
- Sponsor
- Zenith Epigenetics
Solid Tumor
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and…
- Trial name
- NCT06801002
- Testing
- JBZ-001
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jabez Bioscience, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.